Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

PCW-1001, a novel pyrazole compound, modulates the expression of DNA damage response genes

ABSTRACT: As pyrazole and its derivatives have a wide range of biological activities, including anticancer activity, the design of novel pyrazole derivatives has emerged as an important research field. This study describes a novel pyrazole derivative that exerts antitumor and radiosensitizing activities in breast cancer both in vitro and in vivo. We synthesized a novel pyrazole compound N,N-dimethyl-N'-(3-(1-(4-(trifluoromethyl)phenyl)-1H-pyrazol-4-yl)phenyl)azanesulfonamide (PCW-1001) and showed that it inhibited several oncogenic properties of breast cancer both in vitro and in vivo. PCW-1001 induced apoptosis in several breast cancer cell lines. Transcriptome analysis of PCW-1001-treated cells showed that it regulated the DNA damage response, suggesting its potential use in radiotherapy. Indeed, PCW-1001 enhanced the radiation sensitivity of breast cancer cells by modulating the expression of DNA damage response genes. Therefore, our data describe a novel pyrazole compound, PCW-1001, with antitumor and radiosensitizer activities in breast cancer.

ORGANISM(S): Homo sapiens

PROVIDER: GSE190883 | GEO | 2021/12/15

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

PCW-1001, a novel pyrazole compound, modulates the expression of DNA damage response genes

Project description:PCW-1001, a novel pyrazole compound, modulates the expression of DNA damage response genes

| PRJNA788874 | ENA

Pyrimidine Triones as Potential Activators of p53 Mutants

Project description:p53 is a crucial tumor suppressor in vertebrates that is frequently mutated in human cancers. Most mutations are missense mutations that render p53 inactive in suppressing tumor initiation and progression. Developing small molecule drugs to convert mutant p53 into an active, wild-type-like conformation is a significant focus for personalized cancer therapy. Prior research indicates that reactivating p53 suppresses cancer cell proliferation and tumor growth in animal models. Early clinical evidence with a compound selectively targeting p53 mutants with substitutions of tyrosine 220 suggests potential therapeutic benefits of reactivating p53 in patients. This study identifies and examines the UCI-1001 compound series as a potential corrector for several p53 mutations. The findings indicate that UCI-1001 treatment in p53 mutant cancer cell lines inhibits growth and reinstates wild-type p53 activities, including DNA binding, target gene activation, and induction of cell death. Cellular thermal shift assays, conformation-specific immunofluorescence staining, and differential scanning fluorometry suggest that UCI-1001 interacts with and alters the conformation of mutant p53 in cancer cells. These initial results identify pyrimidine trione derivatives of the UCI-1001 series as candidates for p53 corrector drug development.

2024-08-05 | GSE273169 | GEO

MicroRNA profile of drug resistant metaplastic breast cancer cell lines

Project description:Breast cancer cells and two metaplastic breast cancer cell lines were used: a widely available, HS578T, and a novel line isolated from a metaplastic breast cancer tumor, BAS. Doxorubicin and paclitaxel resistant derivatives of these metaplastic lines were generated and miR profiling performed.

2023-01-29 | GSE144445 | GEO

Transcriptome profile of drug resistant metaplastic breast cancer cell lines

Project description:Two metaplastic breast cancer cell lines were used: a widely available, HS578T, and a novel line isolated from a metaplastic breast cancer tumor, BAS. Doxorubicin and paclitaxel resistant derivatives of these lines were generated and transcriptome profiling performed.

2023-01-23 | GSE144113 | GEO

Solis-perez2019 - A fractional mathematical model of breast cancer competition model

Project description:A fractional mathematical model of breast cancer competition model Author links open overlay panelJ.E.Solís-PérezaJ.F.Gómez-Aguilar bA.Atanganac a Tecnológico Nacional de México/CENIDET. Interior Internado Palmira S/N, Col. Palmira, C.P. 62490, Cuernavaca, Morelos, México b CONACyT-Tecnológico Nacional de México/CENIDET. Interior Internado Palmira S/N, Col. Palmira, C.P. 62490, Cuernavaca, Morelos, México c Institute for Groundwater Studies, Faculty of Natural and Agricultural Sciences, University of the Free State, Bloemfontein 9300, South Africa Abstract In this paper, a mathematical model which considers population dynamics among cancer stem cells, tumor cells, healthy cells, the effects of excess estrogen and the body’s natural immune response on the cell populations was considered. Fractional derivatives with power law and exponential decay law in Liouville–Caputo sense were considered. Special solutions using an iterative scheme via Laplace transform were obtained. Furthermore, numerical simulations of the model considering both derivatives were obtained using the Atangana–Toufik numerical method. Also, random model described by a system of random differential equations was presented. The use of fractional derivatives provides more useful information about the complexity of the dynamics of the breast cancer competition model.

2024-09-02 | BIOMD0000000903 | BioModels

Transcriptome sequencing of HepG2 cells upon treatment of Butyrolactone I (PQY09) or derivatives (PQY23_1) butenolide compounds for exploring the targets of PQYs to further study the pharmacological activities

Project description:Transcriptome sequencing (RNA-Seq) of HepG2 cells upon treatment of the 50μM Butyrolactone I (PQY09) or derivatives (PQY23_1) butenolide compounds isolated from marine-derived fungi or DMSO(0.1%) as blank contrast for exploring the targets of PQYs to further study the pharmacological activities Butenolide, a mycotoxin produced by several toxigenic Fusarium species, fre-quently invades many important grains, and evokes a broad spectrum of toxic effects. But several butenolide derivatives, especially the well-known compound butyrolactone I, have been reported to show diverse biological activities, including an-ti-inflammatory , antibacterial , antiviral, antitumor, and α-/β-glucosidase inhibitory activities. So in order to investigate the other effect of PQYs and toxicity target, we used the second-generation transcriptome sequencing(RNA-seq) to determine the expression changes of each gene in HepG2 cells.

2024-05-01 | GSE200538 | GEO

Homo sapiens

Project description:Antitumor Activity of the Novel Flavonoid Oncamex in Preclinical Breast Cancer Models

| PRJNA290000 | ENA

Docosahexaenoic and Arachidonic Free Fatty Acids Exert Different Antitumor Activities on Colorectal Cancer Cells

Project description:Two PUFA, docosahexaenoic (DHA, 22: 6n3) and arachidonic acids (ARA, 20: 4n6), as well as their derivatives such as eicosanoids, regulate different activities, which include changes in receptor signaling, the composition of rafts, cell metabolism, and membrane structures. These also modify the function of transcription factors and their target genes, a key step essential for the function of FA-activated signaling. This work is focused to determine the antitumor actions of these compounds linked to the regulation of gene transcription on HT-29 colorectal cancer. For this, we performed antiproliferative antitumour assay, LDH breakage test, caspase-3 production, and proteome changes were assessed by SWATH-MS quantitative proteomics followed by pathway analysis in order to find out which molecular mechanisms were being affected. In all cases tested, DHA exercised antitumor actions to a higher extent than ARA, acting mainly by means of down-regulating most of the proteasome system particles, while ARA presented a heavy effect on all the six DNA replication helicase particles but did not affect proteasome. The results indicated that both DHA and ARA stopped colorectal cancer growth and proliferation, thus they represent the ideal candidates as chemopreventive agents.

2022-01-28 | PXD008653 | Pride

Expression data in NK150460 treated breast cancer cell lines

Project description:The purpose of this study is to investigate certain genes inuduced/reduced by NK150460, novel compound possessing antitumor activity. To identify genes, time course samples were prepared from NK150460 sensitive and insensitive breast cancer cell lines. By comparing patterns in both sensitive and resistant cell lines, we tried to identify genes specifically modulated by NK150460 treatment. Four breast cance cell lines (3 sensitive cell lines, 1 insensitive cell line) were treated with NK150460 in vitro. 0, 3, 6, 24 hr after drug addition, total RNA were prepared. In total, 16 samples were prepared and subjected to microarray analysis.

2014-09-19 | E-GEOD-61548 | biostudies-arrayexpress

Transcription profiling of human breast adenocarcinoma cell line MCF-7 transfected by TNF alpha receptor 1 to investigate cytoskeleton gene expression associated with resistance to TNF-alfpha

Project description:We used DNA microarray technology to investigate the cytoskeleton gene expression profile associated with the acquisition of cell resistance to TNF-alpha in breast carcinoma cell line (MCF7) versus sensitive cells (1001).

2009-10-31 | E-MEXP-1927 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data